A prospective Phase II study to examine the relationship between quality of life and adverse events of first‐line chemotherapy plus cetuximab in patients with KRAS wild‐type unresectable metastatic colorectal cancer: QUACK trial

Shigeyoshi Iwamoto, Kensei Yamaguchi, Akira Ooki et al.|Cancer Medicine|2018

Cited by 19